What Wall Street Recommends for Walgreens Stock



Earnings expected to decline

Wall Street expects Walgreens Boots Alliance’s (WBA) earnings to continue to decline in coming quarters, reflecting higher reimbursement pressure. Analysts expect Walgreens’ EPS to mark a high-single-digit decline in the second half of fiscal 2019. Meanwhile, EPS are likely to stay low in the first of fiscal 2020.

Weak earnings and challenges in the retail pharmacy segment are expected to pressure Walgreens stock in the near term. Walgreens annualizes its Rite Aid Stores acquisition, owing to which its top-line growth rate is expected to decelerate in the low single digits sequentially.

Sign up for Bagels & Stox, our witty take on the top market and investment news, straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

In comparison, higher interest expenses, a rise in outstanding share count, and reimbursement pressure are expected to hurt CVS Health’s (CVS) bottom line. However, CVS Health’s top line will likely continue to benefit from the acquisition of Aetna.

Article continues below advertisement

Rating and target price

The graph shows that the majority of analysts are suggesting “hold” on Walgreens stock owing to near-term sales and earnings headwinds. Of the 24 analysts covering the stock, 17 recommend a “hold,” four suggest a “buy,” and three maintain a “sell” rating.

Analysts’ consensus target price of $58.95 per share indicates an upside potential of 10.4% based on its closing price of $53.42 on May 10.


More From Market Realist